Literature DB >> 2859508

Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients.

Y Vanrenterghem, L Roels, T Lerut, J Gruwez, P Michielsen, P Gresele, H Deckmyn, M Colucci, J Arnout, J Vermylen.   

Abstract

The incidence of thromboembolic complications was compared retrospectively in 90 cadaveric kidney allograft recipients treated with cyclosporin and low-dose steroids and the same number of cadaveric kidney allograft recipients treated with azathioprine, antilymphocyte globulin, and high-dose steroids. In the cyclosporin group, 17 thromboembolic complications occurred in 13 patients: 10 pulmonary emboli, 1 renal vein thrombosis, 3 deep vein thromboses, and 3 haemorrhoidal thromboses. In the azathioprine group, the only thromboembolic complication was 1 episode of superficial thrombophlebitis. Haemostatic tests in cyclosporin-treated and azathioprine-treated patients and normal subjects (10 in each group) showed increased concentrations of factor VIII C, fibrinogen, antithrombin III, and protein C in the cyclosporin-treated patients. Adenosine-5'-diphosphate-induced platelet aggregation was also significantly enhanced in the cyclosporin group. The effect of cyclosporin on haemostasis may predispose to thromboembolic complications.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859508     DOI: 10.1016/s0140-6736(85)91610-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  15 in total

1.  Acute effects of cyclosporin and cremophor EL on endothelial function and vascular smooth muscle in the isolated rat heart.

Authors:  P Mankad; J Spatenka; Z Slavik; G O'Neil; A Chester; M Yacoub
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

2.  Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells.

Authors:  T E Bunchman; C A Brookshire
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A.

Authors:  A Meyrier; P Simon; G Perret; M C Condamin-Meyrier
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-22

Review 4.  Complications of cyclosporin therapy.

Authors:  B D Kahan; S M Flechner; M I Lorber; C Jensen; D Golden; C T Van Buren
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

6.  Cyclosporin therapy in vivo attenuates the response to vasodilators in the isolated perfused kidney of the rabbit.

Authors:  H S Cairns; L D Fairbanks; J Westwick; G H Neild
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

Review 7.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

9.  Dose response of fish oil versus safflower oil on graft arteriosclerosis in rabbit heterotopic cardiac allografts.

Authors:  K L Yun; J I Fann; M H Sokoloff; L G Fong; G E Sarris; M E Billingham; D C Miller
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

10.  A kidney transplant patient on cyclosporine therapy presenting with dural venous sinus thrombosis: a case report.

Authors:  Senaka Rajapakse; Rosana Gnanajothy; Niroshan Lokunarangoda; Rushika Lanerolle
Journal:  Cases J       Date:  2009-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.